%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2019-11-12T13:09:48-05:00
2019-11-12T13:09:51-05:00
2019-11-12T13:09:51-05:00
Adobe InDesign CC 13.1 (Windows)
uuid:3bb4f379-ce70-497f-84f4-ed37ac34465f
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:9fdcdc99-263b-8949-b8b6-c33ad821d312
proof:pdf
xmp.iid:cdcb5e93-09da-6a40-b349-8fb0a1f5fd02
xmp.did:63c0854f-0da1-a847-8f9e-342f8eb3d8f3
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 13.1 (Windows)
/
2019-11-12T13:09:48-05:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
12 0 obj
<>
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
14 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
44 0 obj
<>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc 8.5 0 0 8.5 171.2281 529.398 Tm
(1.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(The study \037ndings by Stoffel et al support)-10 ( )]TJ
0 -1.2 Td
(which statement?)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 -1.2 Td
[(a. Increased hepcidin levels are associated with)-10 ( )]TJ
0 -1.2 Td
(better iron absorption.)Tj
0 -1.2 Td
[(b. Daily dosing of iron is more bene\037cial than)-10 ( )]TJ
0 -1.2 Td
(alternate-day dosing.)Tj
0 -1.2 Td
[(c. Fractional iron absorption was found to be)-10 ( )]TJ
0 -1.2 Td
(40-50% higher during alternate-day dosing.)Tj
0 -1.2 Td
[(d. Increased serum hepcidin levels persist for)-10 ( )]TJ
0 -1.2 Td
[(72 hours in women with iron de\037ciency)91.9 (.)-9.9 ( )]TJ
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-1.588 -2.894 Td
(2.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(In the sub-analysis by Zhang et al, which form)-10 ( )]TJ
0 -1.2 Td
[(of vitamin D was associated with low all-cause)-10 ( )]TJ
0.01 Tw 0 -1.2 Td
(mortality?)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 Tw 0 -1.2 Td
[(a. V)37 (itamin D)]TJ
0 Tc 4.9555 0 0 4.9555 231.0954 379.5675 Tm
(2)Tj
-0.01 Tc 8.5 0 0 8.5 184.7281 372.198 Tm
[(b. V)37 (itamin D analogs)]TJ
0 -1.2 Td
(c. Hydroxylated vitamin D)Tj
0 -1.2 Td
[(d. V)37 (itamin D)]TJ
0 Tc 4.9555 0 0 4.9555 231.5714 348.9675 Tm
(3)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc 8.5 0 0 8.5 365.8445 529.398 Tm
(3.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(Which is correct regarding the 2019 American)-10 ( )]TJ
0 -1.2 Td
[(Thoracic Society/Infectious Diseases Society)-10 ( )]TJ
0 -1.2 Td
[(of America guideline for management of)-10 ( )]TJ
0 -1.2 Td
(community-acquired pneumonia \(CAP\)?)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 -1.2 Td
[(a. Blood culture should be performed routinely)-10 ( )]TJ
0 -1.2 Td
[(in all patients with CAP)129 (.)]TJ
0 -1.2 Td
[(b. Serum procalcitonin measurement should)-9.9 ( )]TJ
0 -1.2 Td
[(not be used to determine the need for empiric)-10 ( )]TJ
0 -1.2 Td
[(antibiotic therapy)92 (.)]TJ
0 -1.2 Td
[(c. All patients with suspected aspiration)-10 ( )]TJ
0 -1.2 Td
[(pneumonia should receive an antibiotic)-9.9 ( )]TJ
0 -1.2 Td
[(regimen that includes effective coverage of)-10 ( )]TJ
0 -1.2 Td
(anaerobic bacteria.)Tj
0 -1.2 Td
[(d. Follow-up chest imaging should be)-10 ( )]TJ
0 -1.2 Td
(performed routinely after \037ve to seven days.)Tj
ET
endstream
endobj
45 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
/CS0 cs 0.07 scn
/GS0 gs
18 197.28 120.33 558.72 re
f
18 36 539.325 53.473 re
f
BT
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 7 0 0 7 27.8983 78.3659 Tm
(Interested in reprints or posting an article to your )Tj
0 -1.143 Td
[(company)-55.8 (\222s site? There are numerous opportunities for )]TJ
0 -1.143 Td
(you to leverage editorial recognition for the benefit of )Tj
0 -1.143 Td
(your brand. Call us at \(800\) 688-2421 or email us at )Tj
0 -1.143 Td
(reprints@reliasmedia.com.)Tj
25.217 4.571 Td
(Discounts are available for group subscriptions, multiple )Tj
0 -1.143 Td
(copies, site licenses, or electronic distribution. For pricing )Tj
0 -1.143 Td
(information, please contact our Group Account Managers )Tj
0 -1.143 Td
(at groups@reliasmedia.com or \(866\) 213-0844.)Tj
19.248 0 Td
( )Tj
5.969 3.429 Td
[(T)175 (o reproduce any part of R)17.6 (elias Media newsletters for )]TJ
0 -1.143 Td
(educational purposes, please contact The Copyright )Tj
0 -1.143 Td
(Clearance Center for permission at info@copyright.com )Tj
0 -1.143 Td
(or \(978\) 750-8400.)Tj
ET
/CS0 CS 1 SCN
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 138.6633 754.5 cm
0 0 m
437.337 0 l
S
Q
/CS0 cs 1 scn
164.425 274.189 391.566 16.258 re
f
BT
0 scn
0.041 Tc -0.016 Tw 10 0 0 10 319.8918 279.6151 Tm
[(CM)1 (E)16 ( O)4.1 (B)11.9 (J)2.4 (E)24.3 (C)-1.4 (T)14.1 (I)0.5 (VE)9.9 (S)]TJ
ET
1 scn
163.328 542.513 392.414 18.174 re
f
0.25 w
163.391 343.005 392.225 199.383 re
S
BT
0 scn
0.037 Tc -0.012 Tw 10 0 0 10 318.7734 548.7422 Tm
[(C)-3.7 (M)-3 (E)12 ( Q)1.9 (U)-3.3 (E)5.9 (S)4.8 (T)10.1 (ION)-11.3 (S)]TJ
ET
0.07 scn
163.266 607.5 392.475 117.38 re
f
BT
0 0 0 1 k
/GS1 gs
/TT1 1 Tf
-0.02 Tc 0 Tw 9 0 0 9 171.2281 709.446 Tm
[(T)174.8 (o earn credit for this activity)87 (, please follow these instructions:)]TJ
0 Tc 22.102 0 Td
( )Tj
-0.02 Tc -22.102 -1.222 Td
[(1. R)17.5 (ead and study the activity)87 (, using the provided references for further research.)]TJ
0 Tc 29.127 0 Td
( )Tj
-0.02 Tc -29.127 -1.222 Td
[(2. L)17.4 (og on to )]TJ
/TT0 1 Tf
0.02 Tw [(R)17.6 (eliasMedia.com)]TJ
/TT1 1 Tf
0 Tw [( and click on My Account. F)35.9 (irst-time users must register on the site. T)174.8 (ests are taken)-19.9 ( )]TJ
0 -1.222 Td
(after each issue.)Tj
0 Tc 5.741 0 Td
( )Tj
-0.02 Tc -5.741 -1.222 Td
[(3. P)54.7 (ass the online test with a score of 100%; you will be allowed to answer \
the questions as many times as needed)-20.3 ( )]TJ
0 -1.222 Td
[(to achieve a score of 100%.)-20 ( )]TJ
0 Tc 10.468 0 Td
( )Tj
-0.02 Tc -10.468 -1.222 Td
[(4. After successfully completing the test, your browser will be automati\
cally directed to the activity evaluation form,)-19.9 ( )]TJ
0 -1.222 Td
(which you will submit online.)Tj
0 -1.222 Td
(5. Once the completed evaluation is received, a credit letter will be em\
ailed to you.)Tj
ET
/CS0 cs 1 scn
/GS0 gs
163.412 724.88 392.33 17.367 re
f
BT
0 scn
/TT0 1 Tf
0.037 Tc -0.012 Tw 10 0 0 10 310.4554 730.4957 Tm
[(C)-3.7 (M)-3 (E)12 ( I)-1.3 (N)-11.4 (S)4.8 (T)7.7 (R)6.1 (U)2.7 (C)-5.3 (T)10.1 (ION)-11.3 (S)]TJ
1 scn
0.01 Tc 0 Tw 9 0 0 9 164.4585 260.7976 Tm
[(Upon completion of this educational activity)87.1 (, participants should be able to:)]TJ
ET
18 110.765 539.325 54.869 re
f
BT
0 0 0 0 k
/T1_0 1 Tf
0.057 Tc -0.032 Tw 18 0 0 18 29.3567 142.4534 Tm
[([)8.9 (I)-2.2 (N)32 ( FU)-7.2 (T)-9.2 (UR)0.5 (E)57 ( )]TJ
0 Tc 0 Tw 6.562 0 Td
( )Tj
0.013 Tc -0.013 Tw -6.562 -1.2 Td
[(I)-21.9 (S)-23.9 (S)-14.3 (U)-46.2 (E)-36.6 (S])]TJ
/TT0 1 Tf
0 Tc 0 Tw 3.719 0 Td
( )Tj
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
6 0 0 6 25.2 744.168 Tm
(PHYSICIAN EDITOR)Tj
/TT0 1 Tf
0 -1.167 Td
(Stephen A. Brunton, MD)Tj
/TT1 1 Tf
-0.025 Tc 0 -1.167 Td
[(Adjunct P)35.6 (rofessor of Pharmacy P)35.7 (ractice)]TJ
0 -1.167 Td
(College of Pharmacy)Tj
0 Tc 7.469 0 Td
( )Tj
-0.025 Tc -7.469 -1.167 Td
[(R)17.5 (oseman University of Health Sciences)]TJ
0 Tc 13.998 0 Td
( )Tj
-0.025 Tc -13.998 -1.167 Td
[(Salt L)17.4 (ake City)]TJ
/T1_0 1 Tf
0 Tc 0 -2.667 Td
(PEER REVIEWER)Tj
/TT0 1 Tf
0 -1.167 Td
[(Gerald R)17.7 (oberts, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
(Senior Attending Physician )Tj
( )Tj
0 -1.167 Td
[(L)17.4 (ong Island Jewish Medical Center)]TJ
13.107 0 Td
( )Tj
-13.107 -1.167 Td
(NS/LIJ Health Care System)Tj
10.378 0 Td
( )Tj
-10.378 -1.167 Td
[(New Hyde P)54.8 (ark, NY)]TJ
/T1_0 1 Tf
0 -2.333 Td
[(EDITORIAL ADVISOR)92.1 (Y BOARD)]TJ
/TT0 1 Tf
0 -1.167 Td
(James Chan, PharmD, PhD)Tj
/TT1 1 Tf
0 -1.167 Td
[(Associate Clinical P)34.4 (rofessor)]TJ
( )Tj
0 -1.167 Td
(School of Pharmacy)Tj
7.563 0 Td
( )Tj
-7.563 -1.167 Td
[(University of California, San F)54 (rancisco)]TJ
/TT0 1 Tf
0 -1.917 Td
[(William T)156.1 (. Elliott, MD, F)36.2 (A)17.5 (CP)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Assistant Clinical P)33.9 (rofessor of Medicine )]TJ
0 -1.167 Td
[(University of California, San F)54 (rancisco)]TJ
/TT0 1 Tf
0 -2.333 Td
(David Fiore, MD)Tj
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor of F)35.9 (amily Medicine)]TJ
0 -1.167 Td
[(University of Nevada, R)17.1 (eno)]TJ
/TT0 1 Tf
0 -1.917 Td
[(K)17.7 (en Grauer)100.9 (, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor Emeritus in F)35.1 (amily )]TJ
( )Tj
0 -1.167 Td
(Medicine, College of Medicine,)Tj
0 -1.167 Td
(University of Florida)Tj
/TT0 1 Tf
0 -2.333 Td
(Seema Gupta, MD, MSPH)Tj
/TT1 1 Tf
0 -1.167 Td
[(Clinical Assistant P)33.9 (rofessor)100.4 (,)]TJ
0 -1.167 Td
[(Department of F)35.5 (amily and Community)]TJ
0 -1.167 Td
(Health, Joan C. Edwards School of Medicine)Tj
0 -1.167 Td
(Marshall University)Tj
0 -1.167 Td
(Huntington, WV)Tj
/TT0 1 Tf
-0.01 Tc 0 -1.917 Td
[(Harold L. K)17.8 (arpman, MD, F)35.8 (A)17.5 (CC, F)35.7 (A)17.6 (CP)]TJ
/TT1 1 Tf
-0.03 Tc 0 -1.167 Td
[(Clinical P)35.7 (rofessor of Medicine)]TJ
0 Tc 10.349 0 Td
( )Tj
-0.03 Tc -10.349 -1.167 Td
(David Geffen School of Medicine at UCLA)Tj
/TT0 1 Tf
0 Tc 0 -1.917 Td
[(Louis K)17.8 (uritzky)87.5 (, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Clinical Assistant P)33.9 (rofessor)100.4 (, )]TJ
0 -1.167 Td
(University of Florida, Gainesville)Tj
/TT0 1 Tf
0 -1.917 Td
[(Martin S. Lipsky)87.5 (, MD)]TJ
/TT1 1 Tf
-0.03 Tc 0 -1.167 Td
[(Chancellor)100.5 (, South Jordan Campus, R)17.5 (oseman)-29.9 ( )]TJ
0 -1.167 Td
(University of Health Sciences, South Jordan, UT)Tj
/TT0 1 Tf
0 Tc 0 -1.917 Td
[(Joseph E. Scherger)101.6 (, MD, MPH)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Core F)35.8 (aculty)86.9 (,)]TJ
0 -1.167 Td
[(Eisenhower Health F)35.5 (amily Medicine R)16.7 (esidency )]TJ
0 -1.167 Td
[(P)35.7 (rogram,)]TJ
0 -1.167 Td
[(Eisenhower Health Center)99.9 (, L)17.5 (a Quinta, CA)-18.8 (;)]TJ
0 -1.167 Td
[(Clinical P)34.8 (rofessor)100.4 (,)]TJ
0 -1.167 Td
[(K)17.6 (eck School of Medicine,)]TJ
0 -1.167 Td
[(University of Southern California, L)16.8 (os Angeles)]TJ
/TT0 1 Tf
0 -1.917 Td
(Allan J. Wilke, MD, MA)Tj
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor and Chair)]TJ
7.542 0 Td
( )Tj
-7.542 -1.167 Td
[(Department of F)35.5 (amily Medicine)]TJ
12.045 0 Td
( )Tj
-12.045 -1.167 Td
[(W)54.9 (estern Michigan University)]TJ
10.92 0 Td
( )Tj
-10.92 -1.167 Td
[(School of Medicine, K)17.8 (alamazoo)]TJ
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 0 -2.5 Td
(EDITOR)Tj
/TT0 1 Tf
0 Tw 0 -1.25 Td
(Jonathan Springston)Tj
/T1_0 1 Tf
0.01 Tw 0 -2.5 Td
(EDITOR)Tj
/TT0 1 Tf
0 Tw 0 -1.25 Td
(Jason Schneider)Tj
/T1_0 1 Tf
0 -2.5 Td
(EDITORIAL GROUP MANAGER)Tj
/TT0 1 Tf
0 -1.333 Td
(Leslie Coplin)Tj
/T1_0 1 Tf
0 -2.667 Td
[(ACCREDIT)74 (A)74 (TIONS MANAGER)]TJ
/TT0 1 Tf
0 -1.25 Td
(Amy M. Johnson, MSN, RN, CPN)Tj
/CS0 cs 1 scn
/GS0 gs
/TT1 1 Tf
0.01 Tc 9 0 0 9 163.2662 246.9114 Tm
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
(describe new findings in the differential diagnosis and treatment of var\
ious diseases;)Tj
-1.111 -1.222 Td
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
[(describe the advantages, disadvantages, and controversies surrounding th\
e latest advances in the diagnosis)9.8 ( )]TJ
/Span<>> BDC
-1.111 -1.222 Td
[( )-238 ( )]TJ
EMC
1.111 0 Td
(and treatment of disease;)Tj
-1.111 -1.222 Td
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
(identify cost-effective treatment regimens;)Tj
-1.111 -1.222 Td
(\225)Tj
/Span<>> BDC
( )Tj
EMC
1.111 0 Td
(explain the advantages and disadvantages of new disease screening proced\
ures.)Tj
0 0 0 0 k
0 Tc -0.945 -6.187 Td
(Menopausal Hormonal Therapy and Breast)Tj
0 -1.2 Td
[(Cancer Risk: Are Old Data R)16.5 (elevant )]TJ
( )Tj
0 -1.2 Td
[(to T)174.8 (oday)-55.6 (\222s P)35.5 (ractice?)]TJ
22.038 2.4 Td
[(Dapagliflozin T)154.6 (reatment Improves Life)]TJ
0 -1.2 Td
[(Quality for Systolic Heart F)35 (ailure P)54.3 (atients)]TJ
ET
endstream
endobj
46 0 obj
<>
endobj
47 0 obj
<>
endobj
48 0 obj
<>
endobj
53 0 obj
<>
endobj
54 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆"uDsF'OuOD'&2G'j~"7vG?j$O ?O'I?ɟ'$O ?O'I?ɟ'3,Ɵ?gYyV2ee*)U,S,XXVLbbY2Ų++*V(VTPXXQBbbE
ŊnL_//?R_/WU_W+*_WU_W+*_o7M7&o
o7M7&o
:zX.oز>*+zR9OS Mb
endstream
endobj
55 0 obj
<>stream
HtV TT[GdaF@" AVh)YEA@1qq!Xb!֪ш(j+H4ScqiOBf@rNsN}=0 NX
)NmgDԜ,c٦ {3rThUtf1e侇TAo[dN)d+
r[3=9!$7<*A /RNҜ, ; Ρ8(B;הd=nvT*.K+n`ng